Biocept Inc. (BIOC)
0.43
-0.00 (-1.13%)
At close: Jan 16, 2025, 9:00 PM
-1.13% (1D)
| Bid | n/a |
| Market Cap | 450.79K |
| Revenue (ttm) | -3.44M |
| Net Income (ttm) | -34.9M |
| EPS (ttm) | -48.17 |
| PE Ratio (ttm) | -0.009028440938343367 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 572,521 |
| Avg. Volume (20D) | 0 |
| Open | 0.49 |
| Previous Close | 0.43 |
| Day's Range | 0.43 - 0.49 |
| 52-Week Range | 0.43 - 0.49 |
| Beta | 0.59 |
About BIOC
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The compa...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Feb 5, 2014
Employees 50
Stock Exchange NASDAQ
Ticker Symbol BIOC
Website https://biocept.com